NASDAQ:GDTC CytoMed Therapeutics (GDTC) Stock Price, News & Analysis $0.84 -0.06 (-6.18%) As of 10/12/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC Filings About CytoMed Therapeutics Stock (NASDAQ:GDTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytoMed Therapeutics alerts:Sign Up Key Stats Today's Range$0.71▼$0.9850-Day Range$0.78▼$1.0352-Week Range$0.68▼$3.68Volume54,761 shsAverage Volume19,392 shsMarket Capitalization$9.60 millionP/E RatioN/ADividend YieldN/APrice Target$4.16Consensus RatingHold Company Overview CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research programs are designed to use immune cells to recognize and attack cancer cells, with an emphasis on potentially scalable, off-the-shelf treatments. CytoMed’s technology platform includes the development of allogeneic cell therapies derived from healthy donors, including therapies based on gamma-delta T cells and other immune-cell types. Its pipeline is focused primarily on oncology applications, including potential treatments for solid tumors and other cancers. The company conducts research and development activities in Singapore and is advancing its therapeutic candidates through preclinical and clinical development. CytoMed Therapeutics was established as a biotechnology company focused on translating cellular immunotherapy research into cancer treatments.AI Generated. May Contain Errors. Read More CytoMed Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreGDTC MarketRank™: CytoMed Therapeutics scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCytoMed Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCytoMed Therapeutics has a consensus price target of $4.16, representing about 412.7% upside from its current price of $0.81.Amount of Analyst CoverageCytoMed Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about CytoMed Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCytoMed Therapeutics has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CytoMed Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.14% of the float of CytoMed Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytoMed Therapeutics has a short interest ratio ("days to cover") of 1.07, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytoMed Therapeutics has recently increased by 372.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoMed Therapeutics does not currently pay a dividend.Dividend GrowthCytoMed Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.47 News SentimentCytoMed Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CytoMed Therapeutics this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoMed Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions0.04% of the stock of CytoMed Therapeutics is held by institutions.Read more about CytoMed Therapeutics' insider trading history. Receive GDTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GDTC Stock News HeadlinesCytoMed Therapeutics Limited (NASDAQ:GDTC) Stock Short Interest Report for SeptemberOctober 11 at 10:20 AM | americanbankingnews.comCytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBankJune 23, 2026 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)CytoMed Therapeutics Shareholders Approve All Resolutions at May 22 AGMJune 3, 2026 | tipranks.comCytoMed Renames Subsidiary to Drive Asian and International ExpansionMay 11, 2026 | tipranks.comCytoMed Therapeutics Sets May 22, 2026 AGM With Expanded Share-Issuance Mandate on the TableApril 14, 2026 | tipranks.comCytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia ExpansionMarch 31, 2026 | tipranks.comCytoMed Therapeutics Refutes Misleading Claims, Confirms Ongoing First-in-Human TrialJanuary 28, 2026 | tipranks.comSee More Headlines GDTC Stock Analysis - Frequently Asked Questions How have GDTC shares performed this year? CytoMed Therapeutics' stock was trading at $1.3350 at the beginning of 2026. Since then, GDTC shares have decreased by 39.2% and is now trading at $0.8114. How were CytoMed Therapeutics' earnings last quarter? CytoMed Therapeutics Limited (NASDAQ:GDTC) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $0.06 million for the quarter. When did CytoMed Therapeutics IPO? CytoMed Therapeutics (GDTC) raised $11 million in an initial public offering (IPO) on Wednesday, April 12th 2023. The company issued 2,412,369 shares at a price of $4.00-$5.00 per share. How do I buy shares of CytoMed Therapeutics? Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoMed Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Last Earnings9/30/2026Today10/12/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GDTC's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GDTC CIK1873093 Webw2.cytomed.sg Phone65-6250-7738FaxN/AEmployees42Year Founded2018Price Target and Rating Average Price Target for CytoMed Therapeutics$4.16 High Price Target$4.16 Low Price Target$4.16 Potential Upside/Downside+412.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.07 Current Ratio2.64 Quick RatioN/A Sales & Book Value Annual Sales$250 thousand Price / Sales38.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book1.80Miscellaneous Outstanding Shares11,830,000Free FloatN/AMarket Cap$9.60 million OptionableNot Optionable Beta0.06 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:GDTC) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
